Relationship between coronavirus disease 2019 and Parkinson’s disease

Yakubmiyer Musheyev, Farage Ftiha, Henry Jradeh


New literature shows that COVID-19 has negative effects on patients with Parkinson’s disease (PD). COVID-19 is known to produce neurological manifestations and infects the central nervous system. Similarly, the virus also causes neuromuscular complications and involves the peripheral nervous system. Studies show PD patients with a severe COVID-19 infection have a higher mortality rate, worsening in symptoms, and require an increase in drug dosage. These studies suggest that COVID-19 may lead to a more rapid onset of PD, or may increase the risk of developing PD. Furthermore, researchers observed that Motor and nonmotor symptoms significantly worsened in PD patients with COVID compared to PD patients.


COVID-19, PD, Corona virus 2019, severe acute respiratory syndrome coronavirus 2, ACE2

Full Text:



Alomari SO, Abou-Mrad Z, Bydon A. COVID-19 and the central nervous system. Clin neurol neurosurg. 2020;198:106116.

Netland J, Meyerholz DK, Moore S, Cassell M, Perlman S. Severe acute respiratory syndrome coronavirus infection causes neuronal death in the absence of encephalitis in mice transgenic for human ACE2. J virol. 2008;82(15):7264-75.

Warner R. Neurological and neuromuscular manifestations in SARS-CoV-2: Review of Literature and Case Series. Europe PMC. Available at: Accessed on 21 March 2020.

Bantle CM, Phillips AT, Smeyne RJ, Rocha SM, Olson KE, Tjalkens RB. Infection with mosquito-borne alphavirus induces selective loss of dopaminergic neurons, neuroinflammation and widespread protein aggregation. Nature News. Available at: Accessed on 13 September 2019.

Cilia R, Bonvegna S, Straccia G, Andreasi NG, Elia AE, Romito LM et al. Effects of COVID-19 on Parkinson's Disease Clinical Features: A Community-Based Case-Control Study. Movement disorders. 2020;35(8):1287-92.

Radhakrishnan DM, Goyal V. Parkinson's disease: A review. Neurology India. 2018;66(1):S26-35.

Pavel A, Murray DK, Stoessl AJ. COVID-19 and selective vulnerability to Parkinson's disease. Lancet. 2020;19(9):719.

Antonini A, Leta V, Teo J, Chaudhuri KR. Outcome of Parkinson's Disease Patients Affected by COVID-19. Movement disorders. 2020;35(6):905-8.

Mao L, Jin H, Wang M, Hu Y, Chen S, He Q, Chang J et al. Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease 2019 in Wuhan, China. JAMA neurol. 2020;77(6):683-90.

Abboud H, Abboud FZ, Kharbouch H, Arkha Y, El Abbadi N, El Ouahabi A. COVID-19 and SARS-Cov-2 Infection: Pathophysiology and Clinical Effects on the Nervous System. World neurosurg. 2020;140:49-53.

Moriguchi T, Harii N, Goto J, Harada D, Sugawara H, Takamino J et al. A first case of meningitis/encephalitis associated with SARS-Coronavirus-2. Int j infect diseases. 2020;94:55-8.

Gheblawi M, Wang K, Viveiros A, Nguyen Q, Zhong JC, Turner AJ et al. Angiotensin-Converting Enzyme 2: SARS-CoV-2 Receptor and Regulator of the Renin-Angiotensin System: Celebrating the 20th Anniversary of the Discovery of ACE2. Circulation res. 2020;126(10):1456-74.

Mehta P, McAuley DF, Brown M, Sanchez E, Tattersall RS, Manson JJ et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet (London, England). 2020;395(10229):1033-4.

Bohmwald K, Gálvez N, Ríos M, Kalergis AM. Neurologic Alterations Due to Respiratory Virus Infections. Frontiers in cellular neurosc. 2018;12:386.

Yan R, Zhang Y, Li Y, Xia L, Guo Y, Zhou Q. Structural basis for the recognition of SARS-CoV-2 by full-length human ACE2. Science (New York, N.Y.). 2020;367(6485):1444–8.

Baig AM, Khaleeq A, Ali U, Syeda H. Evidence of the COVID-19 Virus Targeting the CNS: Tissue Distribution, Host-Virus Interaction, and Proposed Neurotropic Mechanisms. ACS chemical neurosci. 2020;11(7):995-8.

Paliwal VK, Garg RK, Gupta A, Tejan N. Neuromuscular presentations in patients with COVID-19. Neurolo sci. 2020;41(11):3039-56.

Agergaard J, Leth S, Pedersen TH, Harbo T, Blicher JU, Karlsson P et al. Myopathic changes in patients with long-term fatigue after COVID-19. Clin neurophysiol. 2021;S1388-2457(21)00551-4.

Chan KH, Farouji I, Abu Hanoud A, Slim J. Weakness and elevated creatinine kinase as the initial presentation of coronavirus disease 2019 (COVID-19). Am j emergency med. 2020;38(7):1548.e1-3.

Gefen AM, Palumbo N, Nathan SK, Singer PS, Castellanos-Reyes LJ, Sethna CB. Pediatric COVID-19-associated rhabdomyolysis: a case report. Pediatric nephrol. 2020;35(8):1517-20.

Borku Uysal B, Ikitimur H, Yavuzer S, Islamoglu MS, Cengiz M. Case Report: A COVID-19 Patient Presenting with Mild Rhabdomyolysis. Am j trop med hygiene. 2020;103(2):847-50.

Madia F, Merico B, Primiano G, Cutuli SL, De Pascale G, Servidei S. Acute myopathic quadriplegia in patients with COVID-19 in the intensive care unit. Neurology. 2020;95(11):492-4.

Morley JE, Kalantar‐Zadeh K, Anker SD. COVID‐19: a major cause of cachexia and sarcopenia? J Cachexia, Sarcopenia Muscle. 2020;11(4):863-5.

Sorrentino ZA, Giasson BI, Chakrabarty P. α-Synuclein and astrocytes: tracing the pathways from homeostasis to neurodegeneration in Lewy body disease. Acta neuropathologica. 2019;138(1):1-21.

Xiao Q, Chen S, Le W. Hyposmia: a possible biomarker of Parkinson's disease. Neurosci bull. 2019;30(1):134-40.

Cacabelos R. Parkinson's Disease: From Pathogenesis to Pharmacogenomics. Int j molecular sci. 2017;18(3):551.

Kim CY, Alcalay RN. Genetic Forms of Parkinson's Disease. Seminars in neurol. 2017;37(2):135-46

Jang H, Boltz DA, Webster RG, Smeyne RJ. Viral parkinsonism. Biochimica et biophysica acta. 2009;1792(7):714-21.

Lechien JR, Chiesa-Estomba CM, De Siati DR, Horoi M, Le Bon SD, Rodriguez A. Olfactory and gustatory dysfunctions as a clinical presentation of mild-to-moderate forms of the coronavirus disease (COVID-19): a multicenter European study. Eur arch oto-rhino-laryngol. 2020;277(8):2251-61.

Meng X, Deng Y, Dai Z, Meng Z. COVID-19 and anosmia: A review based on up-to-date knowledge. Am j otolaryngol. 2020;41(5):102581.

Rey NL, Wesson DW, Brundin P. The olfactory bulb as the entry site for prion-like propagation in neurodegenerative diseases. Neurobiol disease. 2018;109(Pt B):226-48.

Papa SM, Brundin P, Fung V, Kang UJ, Burn DJ, Colosimo C et al. Impact of the COVID-19 Pandemic on Parkinson's Disease and Movement Disorders. Movement disorders. 2020;35(5):711-5.

Fasano A, Elia AE, Dallocchio C, Canesi M, Alimonti D, Sorbera C et al. Predictors of COVID-19 outcome in Parkinson's disease. Parkinsonism related disorders. 2020;78:134-7.

Naughton SX, Raval U, Pasinetti GM. Potential Novel Role of COVID-19 in Alzheimer's Disease and Preventative Mitigation Strategies. J Alzheimer's dis. 2020;76(1):21-5.

Calderón-Garcidueñas L, Torres-Jardón R, Franco-Lira M, Kulesza R, González-Maciel A, Reynoso-Robles R. Environmental Nanoparticles, SARS-CoV-2 Brain Involvement, and Potential Acceleration of Alzheimer's and Parkinson's Diseases in Young Urbanites Exposed to Air Pollution. J Alzheimer's dis. 2020;78(2):479-503.

Dauer W, Przedborski S. Parkinson's disease: mechanisms and models. Neuron. 2003;39(6):889-909.

Roberts RF, Wade-Martins R, Alegre-Abarrategui J. Direct visualization of alpha-synuclein oligomers reveals previously undetected pathology in Parkinson's disease brain. Brain. 2015;138(Pt 6):1642-57.

Matschke J, Lütgehetmann M, Hagel C, Sperhake JP, Schröder AS, Edler C et al. Neuropathology of patients with COVID-19 in Germany: a post-mortem case series. Lancet. 2020;19(11):919-29.

Mukerji SS, Solomon IH. What can we learn from brain autopsies in COVID-19? Neurosci letters. 2012;742:135528.